O	0	8	Patterns
O	9	11	of
O	12	22	occurrence
O	23	26	and
O	27	39	implications
O	40	42	of
B-condition	43	52	neratinib
I-condition	52	53	-
I-condition	53	63	associated
I-condition	64	72	diarrhea
O	73	75	in
O	76	84	patients
O	85	89	with
O	90	94	HER2
O	94	95	-
O	95	103	positive
O	104	110	breast
O	111	117	cancer
O	117	118	:
O	119	127	analyses
O	128	132	from
O	133	136	the
O	137	147	randomized
O	148	153	phase
O	154	157	III
O	158	165	ExteNET
O	166	171	trial
O	171	172	.

O	173	175	We
O	176	189	characterized
O	190	198	patterns
O	199	201	of
O	202	212	occurrence
O	213	216	and
O	217	220	the
O	221	227	impact
O	228	230	of
O	231	240	neratinib
O	240	241	-
O	241	251	associated
O	252	260	diarrhea
O	261	263	in
O	264	267	the
O	268	275	absence
O	276	278	of
O	279	287	protocol
O	287	288	-
O	288	296	directed
O	297	310	antidiarrheal
O	311	322	prophylaxis
O	323	325	or
O	326	327	a
O	328	334	formal
O	335	343	diarrhea
O	344	354	management
O	355	359	plan
O	360	365	using
O	366	370	data
O	371	375	from
O	376	384	Extended
O	385	393	Adjuvant
O	394	403	Treatment
O	404	406	of
O	407	413	Breast
O	414	420	Cancer
O	421	425	with
O	426	435	Neratinib
O	436	437	(
O	437	444	ExteNET
O	444	445	)
O	445	446	.

O	447	454	ExteNET
O	455	457	is
O	458	459	a
O	460	471	multicenter
O	471	472	,
O	473	479	double
O	479	480	-
O	480	485	blind
O	485	486	,
O	487	494	placebo
O	494	495	-
O	495	505	controlled
O	505	506	,
O	507	517	randomized
O	518	523	phase
O	524	527	III
O	528	533	trial
O	534	543	involving
O	544	553	community
O	553	554	-
O	554	559	based
O	560	563	and
O	564	572	academic
O	573	585	institutions
O	586	588	in
O	589	591	40
O	592	601	countries
O	601	602	.

B-eligibility	603	608	Women
I-eligibility	609	613	with
I-eligibility	614	618	HER2
I-eligibility	618	619	-
I-eligibility	619	627	positive
I-eligibility	628	633	early
I-eligibility	633	634	-
I-eligibility	634	639	stage
I-eligibility	640	646	breast
I-eligibility	647	653	cancer
I-eligibility	654	658	with
I-eligibility	659	664	prior
I-eligibility	665	673	standard
I-eligibility	674	681	primary
I-eligibility	682	689	therapy
I-eligibility	690	693	and
I-eligibility	694	705	trastuzumab
I-eligibility	705	706	-
I-eligibility	706	711	based
I-eligibility	712	713	(
I-eligibility	713	716	neo
I-eligibility	716	717	)
I-eligibility	717	725	adjuvant
I-eligibility	726	733	therapy
O	734	738	were
O	739	749	randomized
O	750	752	to
B-intervention	753	762	neratinib
O	763	766	240
O	767	769	mg
O	769	770	/
O	770	773	day
O	774	776	or
B-control	777	784	placebo
O	785	788	for
O	789	791	12
O	792	798	months
O	798	799	.

B-outcome-Measure	800	806	Safety
O	806	807	,
O	808	809	a
O	810	819	secondary
O	820	827	outcome
O	827	828	,
O	829	832	was
O	833	841	assessed
O	842	847	using
O	848	851	the
O	852	860	National
O	861	867	Cancer
O	868	877	Institute
O	878	884	Common
O	885	896	Terminology
O	897	905	Criteria
O	906	913	version
O	914	915	3
O	915	916	.
O	916	917	0
O	917	918	.

O	919	925	Health
O	925	926	-
O	926	933	related
O	934	941	quality
O	942	944	of
O	945	949	life
O	950	952	by
O	953	961	diarrhea
O	962	967	grade
O	968	971	was
O	972	980	assessed
O	981	986	using
O	987	997	Functional
O	998	1008	Assessment
O	1009	1011	of
O	1012	1018	Cancer
O	1019	1026	Therapy
O	1026	1027	-
O	1027	1033	Breast
O	1034	1035	(
O	1035	1039	FACT
O	1039	1040	-
O	1040	1041	B
O	1041	1042	)
O	1042	1043	.

B-total-participants	1044	1047	Two
I-total-participants	1048	1056	thousand
I-total-participants	1057	1062	eight
I-total-participants	1063	1070	hundred
I-total-participants	1071	1078	sixteen
O	1079	1084	women
O	1085	1086	(
B-intervention-participants	1086	1090	1408
O	1091	1094	per
O	1095	1100	group
O	1100	1101	)
O	1102	1106	were
O	1107	1113	safety
O	1113	1114	-
O	1114	1123	evaluable
O	1123	1124	.

B-outcome	1125	1130	Grade
I-outcome	1131	1132	3
I-outcome	1133	1136	and
I-outcome	1137	1138	4
I-outcome	1139	1147	diarrhea
O	1148	1156	occurred
O	1157	1159	in
B-iv-bin-abs	1160	1163	561
O	1164	1165	(
B-iv-bin-percent	1165	1167	39
I-iv-bin-percent	1167	1168	.
I-iv-bin-percent	1168	1169	8
I-iv-bin-percent	1169	1170	%
O	1170	1171	)
O	1172	1175	and
B-iv-bin-abs	1176	1177	1
O	1178	1179	(
B-iv-bin-percent	1179	1180	0
I-iv-bin-percent	1180	1181	.
I-iv-bin-percent	1181	1182	1
I-iv-bin-percent	1182	1183	%
O	1183	1184	)
O	1185	1193	patients
O	1194	1198	with
O	1199	1208	neratinib
O	1209	1215	versus
B-cv-bin-abs	1216	1218	23
O	1219	1220	(
B-cv-bin-percent	1220	1221	1
I-cv-bin-percent	1221	1222	.
I-cv-bin-percent	1222	1223	6
I-cv-bin-percent	1223	1224	%
O	1224	1225	)
O	1226	1229	and
B-cv-bin-abs	1230	1231	0
O	1232	1240	patients
O	1241	1245	with
O	1246	1253	placebo
O	1253	1254	,
O	1255	1267	respectively
O	1267	1268	.

O	1269	1271	In
O	1272	1275	the
O	1276	1285	neratinib
O	1286	1291	group
O	1291	1292	,
B-iv-bin-percent	1293	1295	28
I-iv-bin-percent	1295	1296	.
I-iv-bin-percent	1296	1297	6
I-iv-bin-percent	1297	1298	%
O	1299	1301	of
O	1302	1310	patients
O	1311	1314	had
B-outcome	1315	1320	grade
I-outcome	1321	1322	3
I-outcome	1323	1329	events
O	1330	1336	during
O	1337	1342	month
O	1343	1344	1
O	1345	1355	decreasing
O	1356	1358	to
O	1359	1360	â‰¤
O	1361	1362	6
O	1362	1363	%
O	1364	1369	after
O	1370	1375	month
O	1376	1377	3
O	1377	1378	.

O	1379	1382	The
B-outcome	1383	1389	median
I-outcome	1390	1400	cumulative
I-outcome	1401	1409	duration
I-outcome	1410	1412	of
I-outcome	1413	1418	grade
I-outcome	1419	1420	3
I-outcome	1420	1421	/
I-outcome	1421	1422	4
I-outcome	1423	1431	diarrhea
O	1432	1436	with
O	1437	1446	neratinib
O	1447	1450	was
B-iv-cont-median	1451	1452	5
I-iv-cont-median	1453	1457	days
O	1458	1459	(
O	1459	1472	interquartile
O	1473	1478	range
O	1478	1479	,
O	1480	1481	2
O	1481	1482	-
O	1482	1483	9
O	1483	1484	)
O	1484	1485	.

B-outcome	1486	1493	Serious
I-outcome	1494	1503	diarrheal
I-outcome	1504	1510	events
O	1511	1512	(
O	1512	1513	n
O	1514	1515	=
B-iv-bin-abs	1516	1518	22
O	1518	1519	,
B-iv-bin-percent	1520	1521	1
I-iv-bin-percent	1521	1522	.
I-iv-bin-percent	1522	1523	6
I-iv-bin-percent	1523	1524	%
O	1524	1525	)
O	1526	1529	and
B-outcome	1530	1539	diarrheal
I-outcome	1540	1546	events
I-outcome	1547	1556	requiring
I-outcome	1557	1572	hospitalization
O	1573	1574	(
O	1574	1575	n
O	1576	1577	=
B-iv-bin-abs	1578	1580	20
O	1580	1581	,
B-iv-bin-percent	1582	1583	1
I-iv-bin-percent	1583	1584	.
I-iv-bin-percent	1584	1585	4
I-iv-bin-percent	1585	1586	%
O	1586	1587	)
O	1588	1592	were
O	1593	1597	rare
O	1598	1602	with
O	1603	1612	neratinib
O	1612	1613	.

O	1614	1621	Changes
O	1622	1624	in
O	1625	1629	FACT
O	1629	1630	-
O	1630	1631	B
O	1632	1637	total
O	1638	1643	score
O	1644	1646	by
O	1647	1655	diarrhea
O	1656	1661	grade
O	1662	1664	in
O	1665	1668	the
O	1669	1678	neratinib
O	1679	1684	group
O	1685	1688	did
O	1689	1692	not
O	1693	1697	meet
O	1698	1701	the
O	1702	1711	threshold
O	1712	1715	for
O	1716	1726	clinically
O	1727	1736	important
O	1737	1748	differences
O	1748	1749	.

O	1750	1752	In
O	1753	1756	the
O	1757	1764	absence
O	1765	1767	of
O	1768	1781	antidiarrheal
O	1782	1793	prophylaxis
O	1793	1794	,
O	1795	1804	neratinib
O	1804	1805	-
O	1805	1812	related
O	1813	1821	diarrhea
O	1822	1824	is
O	1825	1830	short
O	1830	1831	-
O	1831	1836	lived
O	1837	1840	and
O	1841	1844	not
O	1845	1855	associated
O	1856	1860	with
O	1861	1874	complications
O	1875	1877	or
O	1878	1882	long
O	1882	1883	-
O	1883	1887	term
O	1888	1896	sequelae
O	1896	1897	.

O	1898	1902	This
O	1903	1911	suggests
O	1912	1916	that
O	1917	1925	targeted
O	1926	1936	preventive
O	1937	1947	management
O	1948	1952	with
O	1953	1966	antidiarrheal
O	1967	1978	prophylaxis
O	1979	1984	early
O	1985	1991	during
O	1992	2001	neratinib
O	2002	2011	treatment
O	2012	2014	is
O	2015	2026	appropriate
O	2026	2027	.

O	2028	2042	ClinicalTrials
O	2042	2043	.
O	2043	2046	gov
O	2047	2058	NCT00878709
O	2058	2059	.

O	2060	2070	Registered
O	2071	2072	9
O	2073	2078	April
O	2079	2083	2009
O	2083	2084	.
